TRML - Tourmaline Bio, Inc. Projected Sales Volume
The volatility of Tourmaline Bio, Inc. (TRML) is driven by the integration of AI and robotics into drug development; consequently, GURU.Markets analytics includes this chart of the company's expected sales volume, where the indicator value is 0.00. The creation of an antibody ecosystem for treating the heart and eyes serves to mitigate risks, yet a critical dependence on a single asset creates serious fundamental threats to the business.
Analytical breakdowns for Tourmaline Bio, Inc.
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Tourmaline Bio, Inc.|TRML - Long-Term Debt to Capital|Short-Term Debt to Equity Tourmaline Corp|TRML - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Tourmaline Bio Inc|TRML - Company Long-Term Liabilities|Company Short-Term Debts Tourmaline Bio|Quick Liquidity tourmalinebio.com
- financial results and valuation multiples details:
TRML - Company Net Income|Projected Future Earnings Tourmaline Bio, Inc.|TRML - Business Payback Period|Future Price to Earnings Tourmaline Bio|TRML - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Tourmaline Bio Inc|TRML - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Tourmaline Bio|TRML - Earnings per share for the trailing year|Quarterly EPS earnings growth tourmalinebio.com|TRML - Earnings per share growth in current year|Earnings growth forecast for next year Tourmaline Bio, Inc.
- company sales and revenue statistics:
Fundamental valuation:TRML Tourmaline Bio, Inc.
The commercial success of Tourmaline Bio, Inc. (TRML) depends on bringing innovative IL-6 inhibitors for the treatment of autoimmune diseases to market. By analyzing the company's planned sales volume, an investor can identify the aggregated vector of market revenue expectations, which is formed as a weighted average consensus of market participant forecasts, allowing for an assessment of the monetization potential of its developments and the overall resilience of the business model amid macroeconomic uncertainty.
Competitors of Tourmaline Bio, Inc.
Company Projected Revenue argenx SE (ARGX)|biontech.de - Company Revenue Forecast|Projected Sales Volume ABVX (Abivax S.A.)|ADMA Biologics Inc (ADMA) - Company Expected Sales Volume|PTGX: Company Future Sales Volume|Immunovant Therapeutics - Company Projected Revenue Volume|Kiniksa Pharmaceuticals (KNSA) - Company Projected Revenue|Company Expected Sales Volume grifols.com (GRFS)|Company Future Sales Volume ADPT|Projected Sales Volume Celldex Therapeutics Inc|Company Projected Revenue Aurinia Pharma (AUPH)|BCRX (BioCryst Corp) - Company Future Revenue|Company Projected Revenue Vera Therapeutics, Inc. VERA|DNTH - Company Future Sales Volume|Pharvaris - Projected Sales Volume|ABCL - Projected Sales Volume|Intrexon (PGEN) - Company Projected Revenue|PHAR (Pharming Corp) - Company Projected Revenue|NKTR (Nektar Therapeutics) - Projected Sales Volume|upstreambio.com (UPB) - Company Future Sales|Company Projected Revenue Zenas Biopharma (ZBIO)|Immunome Inc - Company Revenue Forecast|Projected Sales Volume GOSS (Gossamer Corp)|KalVista Corp (KALV) - Company Expected Sales Volume|SEPN: Company Future Sales Volume|Company Future Revenue PVLA (pieris.com)|SVRA: Projected Sales Volume|RIGL (Rigel Pharma) - Company Projected Revenue|ANAB (AnaptysBio Corp) - Projected Sales Volume|Astria Corp (ATXS) - Company Future Sales|Company Projected Revenue enGene Holdings Inc. (ENGN)|RAPT - Company Expected Sales Volume|Aerovate Therapeutics - Company Future Sales Volume|Company Future Revenue ACRS|Kyverna - Projected Sales Volume|Company Future Sales Tiziana Life Sciences, Ltd. TLSA|Cabaletta Bio, Inc. (CABA) - Company Projected Revenue|Company Revenue Forecast VTYX|THTX (Theratechnologies) - Projected Sales Volume|Company Future Sales Volume Avalo Therapeutics, Inc. (AVTX)|Company Future Sales Volume ELDN (Eledon)|Company Future Sales Agenus, Inc|Climb Bio Inc - Company Future Sales Volume|Company Projected Revenue Volume ZURA (zurabio.com)|ATYR - Company Projected Revenue|Company Future Revenue ADAG (Adagene)|ikenaoncology.com (IMA) - Company Projected Revenue|Company Future Sales Volume Shattuck Labs|Company Projected Revenue Equillium Inc|Company Projected Revenue CNTB|Company Projected Revenue Immunic, Inc. (IMUX)|ATRA: Company Expected Revenue|Projected Sales Volume IFRX (InflaRx)|Company Future Revenue XFOR|Adicet - Projected Sales Volume|CELU - Projected Sales Volume|INmune Bio (INMB) - Company Projected Revenue|Barinthus Biotherapeutics PLC - Company Future Revenue|Company Projected Revenue Kezar Life Sciences, Inc|Company Future Sales Volume SAB Biotherapeutics Inc (SABS)|Projected Sales Volume AKTX|Projected Sales Volume enlivex.com (ENLV)|Q32 Bio - Company Future Sales Volume|Company Future Revenue GOVX|Edesa - Projected Sales Volume|Company Future Sales iBio Corporation IBIO|carismatx.com (CARM) - Company Projected Revenue|Company Future Sales Volume xtlbio.com|Company Projected Revenue Bolt Biotherapeutics Inc.|Company Future Sales Volume HCW Biologics Inc (HCWB)|Company Future Sales Volume APVO (Aptevo Therapeutics)|Projected Sales Volume aimimmuno.com (AIM)|Company Projected Revenue Aditxt, Inc. ADTX|GRI: Company Revenue Forecast|XORTX Therapeutics - Projected Sales Volume|Company Expected Sales Volume Vyome Holdings Inc.|REVB (Revelation Bio) - Company Future Sales Volume|INDP: Company Projected Revenue Volume|Company Projected Revenue Scinai Immunotherapeutics|Company Expected Sales Volume CalciMedica Corp CALI|Company Future Sales Volume AFMD (Affimed)|Projected Sales Volume allakos.com (ALLK)|Company Projected Revenue HOOKIPA Pharma HOOK|Company Future Revenue IGMS|ITOS - Company Projected Revenue|oceanbiomedical.com (OCEA) - Company Future Sales Volume|TCBP: Projected Sales Volume|Third Harmonic Bio Inc. (THRD) - Projected Sales Volume
